Clinical trial solutions provider Signant Health has agreed to provide electronic informed consent (eConsent) support for an oncology trial by the University of Bristol in the UK.

The university’s National Institute for Health Research Bristol Biomedical Research Centre (NIHR Bristol BRC) will use Signant Health’s TrialConsent solution for the prostate cancer trial.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the alliance, Signant Health will be able to obtain direct feedback from patients and sites on the TrialConsent’s impact.

The feedback is expected to inform on eConsent’s ability to boost patient comprehension and decrease site burden, while identifying areas of opportunities and challenges for future trials.

Signant Health CEO Mike Nolte said: “We’re excited to see what we can learn from this study and how it helps us improve our patient-centric engagement. These opportunities to support and collaborate with academia for new and novel approaches help us remain at the forefront of technological innovation.”

During the oncology study, Signant Health will carry out qualitative interviews, engage patients and sites, and assess the eConsent impact on sites and patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

TrialConsent is expected to be suitable for trial participants aged 65 years and over and features customisable options, including larger font size, multimedia elements and quizzes.

The solution can also flag sections for review by investigators, as well as monitor, provide and report real-time data.

University of Bristol trials research professor Athene Lane said: “Understanding how patients and sites experience and use eConsent is fundamental to our work.

“We know that data privacy is a big issue so we’re happy that TrialConsent’s password-controls, role-based access rights, and encrypted patient data allows us to offer users increased reassurance around this.”

Last month, Signant Health agreed to offer eConsent support for a neuroscience study at the Shanghai Mental Health Center.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact